Total Payments
$3.1M
2024 Payments
$479,236
Companies
52
Transactions
2,069
Payment Breakdown by Category
Consulting$1.8M (56.8%)
Other$915,164 (29.6%)
Travel$223,413 (7.2%)
Research$161,546 (5.2%)
Food & Beverage$36,615 (1.2%)
Gifts$69.99 (0.0%)
Education$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.8M | 394 | 56.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $773,808 | 243 | 25.0% |
| Travel and Lodging | $223,413 | 527 | 7.2% |
| Unspecified | $161,546 | 174 | 5.2% |
| Honoraria | $120,189 | 20 | 3.9% |
| Food and Beverage | $36,615 | 698 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $17,850 | 5 | 0.6% |
| Grant | $3,318 | 6 | 0.1% |
| Gift | $69.99 | 1 | 0.0% |
| Education | $25.00 | 1 | 0.0% |
Payments by Type
General
$2.9M
1,895 transactions
Research
$161,546
174 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $716,822 | 303 | $0 (2024) |
| GENZYME CORPORATION | $509,563 | 224 | $0 (2024) |
| LEO Pharma AS | $274,656 | 210 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $248,063 | 206 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $144,795 | 54 | $0 (2024) |
| Incyte Corporation | $137,668 | 141 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $134,732 | 134 | $0 (2024) |
| Eli Lilly and Company | $126,558 | 66 | $0 (2024) |
| ABBVIE INC. | $103,080 | 151 | $0 (2024) |
| LEO Pharma Inc. | $83,764 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $479,236 | 301 | GENZYME CORPORATION ($121,307) |
| 2023 | $397,270 | 291 | GENZYME CORPORATION ($75,980) |
| 2022 | $307,481 | 246 | GENZYME CORPORATION ($112,478) |
| 2021 | $366,135 | 157 | PFIZER INC. ($117,604) |
| 2020 | $431,251 | 136 | PFIZER INC. ($203,193) |
| 2019 | $437,258 | 378 | LEO Pharma AS ($99,905) |
| 2018 | $351,594 | 338 | PFIZER INC. ($72,376) |
| 2017 | $321,478 | 222 | PFIZER INC. ($99,831) |
All Payment Transactions
2,069 individual payment records from CMS Open Payments — Page 1 of 83
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $184.34 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $97.35 | General |
| Category: DERMATOLOGY | ||||||
| 12/13/2024 | LEO Pharma Inc. | — | Consulting Fee | Cash or cash equivalent | $5,882.50 | General |
| 12/10/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,820.00 | General |
| Category: Immunology | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $640.68 | Research |
| Study: AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $247.50 | Research |
| Study: AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/29/2024 | Verrica Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $129.69 | General |
| 11/27/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $65.00 | General |
| 11/27/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| 11/27/2024 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $6.00 | General |
| 11/24/2024 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $360.36 | General |
| 11/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $12,350.00 | General |
| Category: Dermatology | ||||||
| 11/23/2024 | LEO Pharma Inc. | — | Travel and Lodging | Cash or cash equivalent | $617.19 | General |
| 11/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $424.00 | General |
| Category: Dermatology | ||||||
| 11/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Travel and Lodging | In-kind items and services | $404.48 | General |
| Category: Dermatology | ||||||
| 11/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Travel and Lodging | In-kind items and services | $300.18 | General |
| Category: Dermatology | ||||||
| 11/23/2024 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $137.44 | General |
| 11/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Travel and Lodging | Cash or cash equivalent | $93.49 | General |
| Category: Dermatology | ||||||
| 11/22/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $92.55 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $8,100.00 | General |
| 11/21/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,730 | 28 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,440 | 25 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $21,092 | 31 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $14,675 | 22 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $11,045 | 3 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP COMPARISON STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-121 AND IDP-121 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $9,348 | 1 |
| PROTOPIC APPLES | LEO Pharma AS | $9,240 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,423 | 12 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $4,920 | 5 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $4,466 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $3,428 | 7 |
| CIBINQO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | GENZYME CORPORATION | $2,750 | 7 |
| A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months to < 6 Years With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,750 | 5 |
| EFFECT OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE GEL ON THE HPA AXIS AND CALCIUM METABOLISM IN ADOLESCENT SUBJECTS AGED 12 TO 16 YEARS, 11 MONTHS WITH SCALP AND BODY PSORIASIS | LEO Pharma AS | $1,720 | 1 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $1,336 | 1 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| SLR - Burden of Atopic Dermatitis in Pediatric Patients and their Caregivers: A Systematic Literature Review (Pediatric Burden MS) | SANOFI-AVENTIS U.S. LLC | $1,015 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $841.65 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $765.05 | 2 |
| Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | GENZYME CORPORATION | $500.00 | 1 |
| A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged greater than or equal to 6 to less than 18 Years With Atopic Dermati | SANOFI-AVENTIS U.S. LLC | $402.68 | 1 |
| Real-world Effectiveness of Dupilumab in Atopic Dermatitis (AD): Improvement in AD Signs as Assessed by the Investigator Global Assessment (IGA) in an Electronic Medical Records Dataset | SANOFI-AVENTIS U.S. LLC | $289.09 | 1 |
| A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged 6 to <18 Years With Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $173.40 | 1 |
| Modernizing Medicine: IGA & NRS | SANOFI-AVENTIS U.S. LLC | $152.19 | 1 |
About Dr. Lawrence Eichenfield, M.D
Dr. Lawrence Eichenfield, M.D is a Pediatric Dermatology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477624138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Eichenfield, M.D has received a total of $3.1M in payments from pharmaceutical and medical device companies, with $479,236 received in 2024. These payments were reported across 2,069 transactions from 52 companies. The most common payment nature is "Consulting Fee" ($1.8M).
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Dermatology
- Location San Diego, CA
- Active Since 11/13/2006
- Last Updated 12/18/2025
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1477624138
Products in Payments
- DUPIXENT (Biological) $636,264
- EUCRISA (Drug) $373,656
- DUPIXENT DUPILUMAB INJECTION (Biological) $121,292
- CIBINQO (Drug) $98,579
- DUPIXENT (Drug) $92,665
- OPZELURA (Drug) $74,332
- Enbrel (Biological) $57,650
- NO PRODUCT DISCUSSED (Drug) $32,472
- RINVOQ (Biological) $29,996
- ADBRY (Biological) $25,799
- TAPINAROF (Drug) $25,064
- Zoryve (Drug) $23,817
- QBREXZA (Drug) $21,809
- COSENTYX (Biological) $19,732
- VTAMA (Drug) $18,321
- Seysara (Drug) $18,150
- ATOPIC DERMATITIS - DISEASE (Drug) $18,053
- Otezla (Drug) $17,527
- Cabtreo (Drug) $16,157
- TREMFYA (Drug) $11,796
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Dermatology Doctors in San Diego
Dr. Wynnis Tom, M.d, M.D
Pediatric Dermatology — Payments: $42,421
Pediatric Dermatology $42,421
Jessica Sprague, Md, MD
Pediatric Dermatology — Payments: $908.67
Pediatric Dermatology $908.67
George Hightower
Pediatric Dermatology — Payments: $182.07
Pediatric Dermatology $182.07
Dr. Neil Gibbs, M.d, M.D
Pediatric Dermatology — Payments: $124.26
Pediatric Dermatology $124.26
Dr. Heather Gochnauer, Md, MD
Pediatric Dermatology
Pediatric Dermatology